These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 2412423

  • 1. [Clinical evaluation of cernilton in the treatment of the benign prostatic hypertrophy].
    Horii A, Iwai S, Maekawa M, Tsujita M.
    Hinyokika Kiyo; 1985 Apr; 31(4):739-46. PubMed ID: 2412423
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Clinical evaluation of Cernilton on benign prostatic hypertrophy--a multiple center double-blind study with Paraprost].
    Maekawa M, Kishimoto T, Yasumoto R, Wada S, Harada T, Ohara T, Okajima E, Hirao Y, Ohzono S, Shimada K.
    Hinyokika Kiyo; 1990 Apr; 36(4):495-516. PubMed ID: 1696065
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cernilton for benign prostatic hyperplasia.
    Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G.
    Cochrane Database Syst Rev; 2000 Apr; (2):CD001042. PubMed ID: 10796739
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L.
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis].
    Apolikhin OI, Aliaev IuG, Sivkov AV, Vinarov AZ, Oshchepkov VN, Keshishev NG, Bedretdinova DA, Akhvlediani ND.
    Urologiia; 2010 Oct; (1):29-34. PubMed ID: 20891044
    [Abstract] [Full Text] [Related]

  • 16. Dietary supplements for benign prostatic hyperplasia: an overview of systematic reviews.
    Kim TH, Lim HJ, Kim MS, Lee MS.
    Maturitas; 2012 Nov; 73(3):180-5. PubMed ID: 22883375
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Conservative treatment of benign prostatic hypertrophy: reevaluation of the effect of eviprostat by subjective symptoms and uroflowmetry].
    Matsuura T, Wakabayashi A, Kaneko S, Kurita T.
    Hinyokika Kiyo; 1986 Jun; 32(6):903-6. PubMed ID: 2429533
    [Abstract] [Full Text] [Related]

  • 19. [Conservative treatment of benign prostatic hypertrophy--clinical effects of increased administration of Hachimijiogan and the relation between these effects and the "Sho" of Chinese medicine].
    Yachiku S, Kaneko S, Matsuura T, Akiyama T, Kurita T.
    Hinyokika Kiyo; 1985 Mar; 31(3):545-51. PubMed ID: 2411117
    [Abstract] [Full Text] [Related]

  • 20. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study.
    Wagenlehner FM, Schneider H, Ludwig M, Schnitker J, Brähler E, Weidner W.
    Eur Urol; 2009 Sep; 56(3):544-51. PubMed ID: 19524353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.